NRS also showed higher reproducibility when measuring pain exacerbations (Cohen's K of 0.86 for NRS vs. 0.53 for VRS) while the reproducibility of the two scales was similar in evaluating ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine) ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ ...

Perioperative posterior cervical muscle plane block decreased numerical pain rating scores vs anesthesia alone in posterior cervical spine surgery.

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

Patients with and without obesity experienced significant pain reductions and improved functioning following telerehabilitation for chronic musculoskeletal pain.

(VRS): Verbal Rating Scales; (BP-EP): Breakthrough or intense Episodic Pain; (CI): Confidence Interval. CB participated in the design of the study, performed the statistical analysis and drafted ...